Cargando…
The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats
RATIONALE: Development and progression of cardiovascular diseases, including hypertension, are often associated with impaired nitric oxide synthase (NOS) function and nitric oxide (NO) deficiency. Current treatment strategies to restore NO bioavailability with organic nitrates are hampered by undesi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735329/ https://www.ncbi.nlm.nih.gov/pubmed/29268201 http://dx.doi.org/10.1016/j.redox.2017.12.004 |
_version_ | 1783287185223450624 |
---|---|
author | Paulo, Luciano L. Cruz, Josiane Campos Zhuge, Zhengbing Carvalho-Galvão, Alynne Brandão, Maria C.R. Diniz, Thiago F. Haworth, Sarah McCann Athayde-Filho, Petrônio F. Lemos, Virginia S. Lundberg, Jon O. Montenegro, Marcelo F. Braga, Valdir A. Carlström, Mattias |
author_facet | Paulo, Luciano L. Cruz, Josiane Campos Zhuge, Zhengbing Carvalho-Galvão, Alynne Brandão, Maria C.R. Diniz, Thiago F. Haworth, Sarah McCann Athayde-Filho, Petrônio F. Lemos, Virginia S. Lundberg, Jon O. Montenegro, Marcelo F. Braga, Valdir A. Carlström, Mattias |
author_sort | Paulo, Luciano L. |
collection | PubMed |
description | RATIONALE: Development and progression of cardiovascular diseases, including hypertension, are often associated with impaired nitric oxide synthase (NOS) function and nitric oxide (NO) deficiency. Current treatment strategies to restore NO bioavailability with organic nitrates are hampered by undesirable side effects and development of tolerance. In this study, we evaluated NO release capability and cardiovascular effects of the newly synthesized organic nitrate 1, 3-bis (hexyloxy) propan-2-yl nitrate (NDHP). METHODS: A combination of in vitro and in vivo approaches was utilized to assess acute effects of NDHP on NO release, vascular reactivity and blood pressure. The therapeutic value of chronic NDHP treatment was assessed in an experimental model of angiotensin II-induced hypertension in combination with NOS inhibition. RESULTS: NDHP mediates NO formation in both cell-free system and small resistance arteries, a process which is catalyzed by xanthine oxidoreductase. NDHP-induced vasorelaxation is endothelium independent and mediated by NO release and modulation of potassium channels. Reduction of blood pressure following acute intravenous infusion of NDHP was more pronounced in hypertensive rats (two-kidney-one-clip model) than in normotensive sham-operated rats. Toxicological tests did not reveal any harmful effects following treatment with high doses of NDHP. Finally, chronic treatment with NDHP significantly attenuated the development of hypertension and endothelial dysfunction in rats with chronic NOS inhibition and angiotensin II infusion. CONCLUSION: Acute treatment with the novel organic nitrate NDHP increases NO formation, which is associated with vasorelaxation and a significant reduction of blood pressure in hypertensive animals. Chronic NDHP treatment attenuates the progression of hypertension and endothelial dysfunction, suggesting a potential for therapeutic applications in cardiovascular disease. |
format | Online Article Text |
id | pubmed-5735329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-57353292017-12-21 The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats Paulo, Luciano L. Cruz, Josiane Campos Zhuge, Zhengbing Carvalho-Galvão, Alynne Brandão, Maria C.R. Diniz, Thiago F. Haworth, Sarah McCann Athayde-Filho, Petrônio F. Lemos, Virginia S. Lundberg, Jon O. Montenegro, Marcelo F. Braga, Valdir A. Carlström, Mattias Redox Biol Research Paper RATIONALE: Development and progression of cardiovascular diseases, including hypertension, are often associated with impaired nitric oxide synthase (NOS) function and nitric oxide (NO) deficiency. Current treatment strategies to restore NO bioavailability with organic nitrates are hampered by undesirable side effects and development of tolerance. In this study, we evaluated NO release capability and cardiovascular effects of the newly synthesized organic nitrate 1, 3-bis (hexyloxy) propan-2-yl nitrate (NDHP). METHODS: A combination of in vitro and in vivo approaches was utilized to assess acute effects of NDHP on NO release, vascular reactivity and blood pressure. The therapeutic value of chronic NDHP treatment was assessed in an experimental model of angiotensin II-induced hypertension in combination with NOS inhibition. RESULTS: NDHP mediates NO formation in both cell-free system and small resistance arteries, a process which is catalyzed by xanthine oxidoreductase. NDHP-induced vasorelaxation is endothelium independent and mediated by NO release and modulation of potassium channels. Reduction of blood pressure following acute intravenous infusion of NDHP was more pronounced in hypertensive rats (two-kidney-one-clip model) than in normotensive sham-operated rats. Toxicological tests did not reveal any harmful effects following treatment with high doses of NDHP. Finally, chronic treatment with NDHP significantly attenuated the development of hypertension and endothelial dysfunction in rats with chronic NOS inhibition and angiotensin II infusion. CONCLUSION: Acute treatment with the novel organic nitrate NDHP increases NO formation, which is associated with vasorelaxation and a significant reduction of blood pressure in hypertensive animals. Chronic NDHP treatment attenuates the progression of hypertension and endothelial dysfunction, suggesting a potential for therapeutic applications in cardiovascular disease. Elsevier 2017-12-11 /pmc/articles/PMC5735329/ /pubmed/29268201 http://dx.doi.org/10.1016/j.redox.2017.12.004 Text en © 2017 Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Paulo, Luciano L. Cruz, Josiane Campos Zhuge, Zhengbing Carvalho-Galvão, Alynne Brandão, Maria C.R. Diniz, Thiago F. Haworth, Sarah McCann Athayde-Filho, Petrônio F. Lemos, Virginia S. Lundberg, Jon O. Montenegro, Marcelo F. Braga, Valdir A. Carlström, Mattias The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats |
title | The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats |
title_full | The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats |
title_fullStr | The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats |
title_full_unstemmed | The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats |
title_short | The novel organic mononitrate NDHP attenuates hypertension and endothelial dysfunction in hypertensive rats |
title_sort | novel organic mononitrate ndhp attenuates hypertension and endothelial dysfunction in hypertensive rats |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735329/ https://www.ncbi.nlm.nih.gov/pubmed/29268201 http://dx.doi.org/10.1016/j.redox.2017.12.004 |
work_keys_str_mv | AT paulolucianol thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT cruzjosianecampos thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT zhugezhengbing thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT carvalhogalvaoalynne thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT brandaomariacr thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT dinizthiagof thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT haworthsarahmccann thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT athaydefilhopetroniof thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT lemosvirginias thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT lundbergjono thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT montenegromarcelof thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT bragavaldira thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT carlstrommattias thenovelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT paulolucianol novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT cruzjosianecampos novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT zhugezhengbing novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT carvalhogalvaoalynne novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT brandaomariacr novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT dinizthiagof novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT haworthsarahmccann novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT athaydefilhopetroniof novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT lemosvirginias novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT lundbergjono novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT montenegromarcelof novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT bragavaldira novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats AT carlstrommattias novelorganicmononitratendhpattenuateshypertensionandendothelialdysfunctioninhypertensiverats |